Mon, Oct 11, 2004
BSI to present at Medtech Insight conference
Study demonstrates that a first-of-its-kind injectable adhesive, from Bone Solutions Inc., is able to attach tendon to bone and bone to bone — suggesting the potential to revolutionize knee and shoulder surgeries in humans and animals.
Privately held Bone Solutions, Inc. ("BSI") (www.bonesolutionsinc.com ) announced today that its magnesium-based, bio-absorbable adhesive compound has successfully tested against leading products in the orthopedic cement/filler markets, providing significantly superior strength compared to these products, and thus potentially eliminating the need for screws, plates and other traditional tools used widely in orthopedic surgeries.
"We believe this has the potential of revolutionizing certain orthopedic surgical procedures, starting with the ACL market, and that of extremities, since our ‘solution' reduces the time it takes for hand, shoulder, ankle injuries to heal. It also could prove invaluable to the sports medicine industry—including both humans and animals," said Thomas Lally, Chairman and President of BSI.
"While current formulations of injectable calcium phosphate compounds are biocompatible, most are not absorbable, or take too long to be absorbed—thereby hindering new bone growth in the repair process," added Lally. “On the other hand, BSI's inorganic compound not only has powerful adhesive qualities and is bio-absorbable and non-toxic, but it also is injectable. Most importantly, being magnesium-based, it overcomes many of the limitations of today's calcium-based cements and fillers.” The Company is presenting at the Medtech Insight "Investment in Innovation" conference in Boston, Oct. 21-22. Alicia L. Bertone, D.V.M., Ph.D., professor of veterinary medicine and equine orthopedic surgery at The Ohio State University “(OSU”), will disclose results of recent testing at OSU.
“The BSI compound of magnesium oxide and biodegradable magnesium monophosphate adhered bone and tendon within bone tunnels sufficiently to significantly augment, or potentially be used independently, in ACL reconstruction. Indeed, our tests showed powerful adhesive properties exceeding 1000 neutons, equivalent to 225 pounds of force, which could be sufficient to contain even fracture fragments in comminuted fracture repair."
Bone Solutions Inc. is a privately held corporation headquartered in Dallas, Tex. “BSI” owns exclusive rights to a breakthrough bone-adhesive technology platform offering a revolutionary solution to attaching ligaments and tendons to bone as well as bone to bone—a first in medical history. The Company is presently seeking early-stage investment funding and new strategic relationships in order to complete regulatory testing and commence commercialization of the product across multiple markets.